AbCellera Biologics Inc. (ABCL) has a negative trailing P/E of -6.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -14.44%.
Criteria proven by this page:
Overall SharesGrow Score: 63/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | 28,795.0 | 0.00 | 766.43 | 1,007.55 | - |
| 2019 | -5,738.5 | 9.33 | 1,237.61 | 1,092.66 | - |
| 2020 | 90.6 | -0.03 | 12.98 | 46.22 | - |
| 2021 | 25.7 | 0.34 | 3.84 | 10.51 | - |
| 2022 | 18.2 | 0.00 | 2.34 | 5.95 | - |
| 2023 | -11.3 | 0.06 | 1.43 | 43.42 | - |
| 2024 | -5.3 | -0.68 | 0.82 | 29.91 | - |
| 2025 | -7.0 | 0.64 | 0.90 | 13.60 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $0.00 | $8.83M | $309K | 3.5% |
| 2019 | $-0.02 | $11.61M | $-2.42M | -20.8% |
| 2020 | $0.44 | $233.16M | $118.92M | 51% |
| 2021 | $0.48 | $375.2M | $153.46M | 40.9% |
| 2022 | $0.50 | $485.42M | $158.52M | 32.7% |
| 2023 | $-0.51 | $38.03M | $-146.4M | -385% |
| 2024 | $-0.55 | $28.83M | $-162.86M | -564.8% |
| 2025 | $-0.49 | $75.13M | $-146.41M | -194.9% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.65 | $-0.70 – $-0.60 | $29.89M | $18.1M – $52.75M | 4 |
| 2027 | $-0.66 | $-0.66 – $-0.65 | $37.04M | $25.32M – $65.44M | 3 |
| 2028 | $-0.78 | $-0.85 – $-0.65 | $55.18M | $36.85M – $96.92M | 3 |
| 2029 | $-0.75 | $-1.48 – $-0.42 | $72.24M | $48.24M – $126.89M | 1 |
| 2030 | $-0.59 | $-1.17 – $-0.34 | $117.61M | $78.53M – $206.56M | 1 |
